Artelo Biosciences, Inc. (NASDAQ: ARTL) had a significant uptick in the most recent trading session, as its shares closed at $14.32, up 42.49%. This notable rising trend followed the presentation of positive preclinical results about its experimental antidepressant drug, ART12.11, at a prestigious scientific conference.
Innovative Results at the ICRS Symposium
New preclinical findings for Artelo’s patented cocrystal of CBD and TMP, ART12.11, were presented at the 35th Annual International Cannabinoid Research Society (ICRS) Symposium, which took place in Bloomington, Indiana, from July 6–10.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Matt Jones, a researcher in Professor Steven Laviolette’s group at the University of Western Ontario, published the evidence in a scientific poster titled “ART12.11, A Novel Cannabidiol:Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms.”
Effectiveness in Relation to Top Antidepressants
A 28-day course of therapy with ART12.11 dramatically restored depression-like behaviors in male rats under prolonged stress, according to the preclinical investigation. The compound’s behavioral effects, such as enhanced social drive and better sucrose preference, were quite similar to those of sertraline (Zoloft), a well-known SSRI.
However, ART12.11 demonstrated a notable edge over sertraline by effectively reversing stress-related spatial and short-term memory deficits—cognitive impairments commonly unaddressed by current antidepressants.
Setting Up for a Market Worth Billions of Dollars
The potential of ART12.11 as a unique contender in the projected multibillion-dollar antidepressant industry is highlighted by its dual-action therapeutic profile, which combines mood-enhancing and cognitive-restorative advantages.
Artelo emphasized that prior research on animals shown that ART12.11 performed better in terms of pharmacokinetic and behavioral characteristics than both CBD and even Epidiolex. This most recent trial confirms the compound’s ability to address unmet requirements in treating depression, especially in cases where cognitive impairment is evident, and represents the first direct comparison with a top-tier SSRI.
A New Approach to Mental Health Treatment
Artelo Biosciences is upbeat about ART12.11’s prospects, highlighting its exceptional effectiveness in the emotional and cognitive areas. According to the business, this combination may distinguish ART12.11 from other treatments and fill a significant gap in the available alternatives for mental health care.
